| Name | Title | Contact Details |
|---|---|---|
Amanda Cannon |
Director, Human Resources | Profile |
Jay Kirksey |
Chief Human Resources Officer | Profile |
Michael Xu |
Chief Financial Officer | Profile |
RESRG Automotive is a global automotive supplier formed from the merger of Rehau Automotive and SRG Global Automotive, officially launched in April 2025. Headquartered in Troy, Michigan, with a European base in Rehau, Germany, the company operates 22 production sites across multiple countries, including Germany, France, and India. With a workforce of around 10,000 employees, RESRG projects pro-forma sales of €1.7 billion. The company specializes in polymer-based exterior and functional systems, offering products such as bumpers, grilles, lamp bezels, and roof panels. RESRG employs advanced manufacturing processes like injection molding and galvanizing, focusing on combining aesthetic appeal with functional performance. The company aims to partner with leading automakers to provide innovative solutions in automotive design and technology.
GO ARMY I BEAT NAVY! The U.S. Military Academy competes as ARMY WEST POINT in a broad range of NCAA D-1 and D-2 sports. At West Point, its all fun and games for ARMY fans, but every cadet on the field or court understands that competition through their sport is a critical component for developing their leadership and teamwork skills, and especially for building personal bonds. West Points competitive sports programs support the Army values of loyalty, duty, respect, selfless service, honor, integrity, and personal courage. It is designed to teach these values in an athletic setting. The nature of competitive sports provides opportunities that are difficult to replicate in the conventional classroom, in other extracurricular activities, or in military field training.
Modern management software for gyms, martial arts schools, yoga studios and membership clubs.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.